<DOC>
	<DOCNO>NCT02221999</DOCNO>
	<brief_summary>The investigator hypothesize paclitaxel combine cisplatin weekly-based regimen neoadjuvant chemotherapy effective tolerable locally advanced breast cancer . In patient sub-type advanced breast cancer , neo-adjuvant chemotherapy combine endocrine therapy may improve pathological remission rate . Premenopausal patient triple negative breast caner hormonal receptor positve breast cancer patient randominzed neoadjuvant chemotherapy combine endocrine therapy .</brief_summary>
	<brief_title>Weekly Paclitaxel Cisplatin Treat Hormone Receptor Positive Triple Negative Breast Cancer Patients</brief_title>
	<detailed_description>In trial , patient ER PR positive breast cancer separately randomize chemotherapy chemotherapy combine endocrine therapy accord menstrual status . Letrozole postmenopausal woman ovarian function suppression premenopausal woman . Patients triple negative breast cancer randomize neoadjuvant chemotherapy combine ovarian function suppression premenopausal . Postermenopausal patient triple negative breast caner neoadjuvant chemotherapy . Patients Her2 overexpression obtain anti-Her2 target therapy . This study amend 1:2 ratio control neoadjuvant chemotherapy combination endocrine therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Women age ≥18years ≤70 year ; 2 . At least measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) . Histologically confirm invasive breast cancer , tumor size ≥2 cm , T24 N02M0 ; 3 . ER/PR/HER2 Ki67 status detect core biopsy . ER and/or PR positive define &gt; 1 % stain cells.HER2positive define immunohistochemistry ( IHC ) 3+ ratio HER2 gene signal chromosome 17 signal &gt; 2.0 HER2 gene copy &gt; 6.0 . 4 . No prior systemic locoregional treatment breast cancer ; 5 . Adequate bone marrow function : WBC≥4.0×109/L , Absolute neutrophil count（ANC）≥1.5×109/L , Platelets（PLT）≥100×109/L , Hemoglobin（Hb）≥90g/L ; aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) ≤1.5 upper normal limit ( UNL ) , creatinine≤1.5 UNL , bilirubin≤1.5UNL ; 6 . No obvious main organ dysfunction . 1 . Unwilling unable use acceptable method contraception 8 week ( include 8 week ) final dose test drug ; 2 . Patient pregnant breast feeding ; 3 . Inflammatory breast cancer metastatic breast cancer ; 4 . Any evidence sense motor nerve disorder ; 5 . Patients medical condition taht indicate intolerant neoadjuvant therapy , include uncontrolled cardiovascular disease , severe infection ; 6 . Any concurrent malignancy breast cancer ; 7 . Know severe hypersensitivity drug study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>